12:13 PM EDT, 07/10/2024 (MT Newswires) -- United Therapeutics ( UTHR ) said Wednesday its late-stage study of Tyvaso inhalation solution to treat idiopathic pulmonary fibrosis has reached full enrollment.

The 597-patient TETON 2 study will evaluate the safety and efficacy of nebulized Tyvaso in subjects with idiopathic pulmonary fibrosis over a 52-week period at sites outside of the US and Canada.

The company said top-line data are expected in the second half of 2025.

Idiopathic pulmonary fibrosis is a scarring disease of the lungs of an unknown cause.

Price: 324.22, Change: +1.57, Percent Change: +0.49